ASLAN Pharmaceuticals

MEI Pharma, Inc. said on 22 July that its board of directors unanimously agreed to hire a financial consultant that can help the company assess strategic alternatives to maximize the value of its ass

Sanofi ’s Dupixent (dupilumab) has received marketing authorization in India, after a long-running back-and-forth with regulatory authorities over clinical trial-related exemptions in the country. The

ASLAN Pharmaceuticals Pte Ltd believes it has a competitive dosing profile for its IL-13 inhibitor eblasakimab in atopic dermatitis and other allergic inflammatory conditions, based on new Phase II r

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Talaris Calls It Quits In Reverse-Merge